ANOLAMINERISKOFHEMORRHAGICSTROKE：出血性中风的风险anolamine.docVIP

PHENYLPROPANOLAMINE RISK OF HEMORRHAGIC STROKE: Final Report of The Hemorrhagic Stroke Project May 10, 2000 Prepared by: Ralph I. Horwitz, M.D. Harold H. Hines Jr. Professor of Medicine and Epidemiology Yale University School of Medicine Lawrence M. Brass, M.D. Professor of Neurology and Epidemiology and Public Health Yale University School of Medicine Walter N. Kernan, M.D. Associate Professor of Medicine Yale University School of Medicine Catherine M. Viscoli, Ph.D. Associate Research Scientist Yale University School of Medicine On Behalf of the HSP Investigators EXECUTIVE SUMMARY Case reports have linked exposure to phenylpropanolamine (PPA) to the occurrence of hemorrhagic stroke. Many of the affected patients have been young women using PPA as an appetite suppressant, often after a first dose. To further examine the association between PPA and hemorrhagic stroke, we designed a case-control study involving men and women ages 18 to 49 years who were hospitalized with a subarachnoid hemorrhage (SAH) or intracerebral hemorrhage (ICH). Eligible case subjects had no prior history of stroke and were able to participate in an interview within 30 days of their event. Case subjects were recruited from hospitals in four geographic regions of the United States. For each case subject, random digit dialing was used to identify two control subjects who were matched on age, gender, race, and telephone exchange. Cases and control subjects were interviewed to ascertain their medical history, health behaviors, and medication usage. A subject was classified as exposed to PPA if they reported use within 3 days of the stroke event for case subjects or a corresponding date for control subjects, and the exposure was verified. The final study cohort comprised 702 case subjects and 1376 control subjects. All control subjects were matched to their case subjects on gender and telephone exchange. Age matching was successful for 1367 controls (99%) and ethnicity matching w